Neurology

Showing 15 posts of 52 posts found.

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024
Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health

Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …

NICE recommends migraine treatment for NHS use

April 11, 2024
Medical Communications NHS, NICE, Neurology, migraine

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …

PureTech Health launches Seaport Therapeutics

April 9, 2024
Business Services Financing, Neurology, PureTech Health, launch

PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to patients and unlock value for …

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

March 25, 2024
Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only …

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

March 21, 2024
Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …

Amneal and Zambon Biotech enter agreement for Parkinson’s treatment

February 28, 2024
Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement

Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …

Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment

February 21, 2024
Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical

Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …

argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment

February 20, 2024
Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA

argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …

Regenxbio announces positive data from trial for MPS II treatment

February 8, 2024
Research and Development Hunter syndrome, MPS II, Neurology, Regenxbio, clinical trial

Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …

milad-fakurian-58z17lnvs4u-unsplash_2

Vivet Therapeutics gains €4.9m for gene therapy development

February 2, 2024
Research and Development CTX, Neurology, Vivet Therapeutics, funding, gene therapy

Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a …

FDA clears Aruna Bio’s IND for AB126 to enter clinical trials

January 17, 2024
Research and Development Aruna Bio, FDA, IND, Neurology, clinical trials

Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …

FDA approves AstraZeneca and Ionis’s Wainua

December 22, 2023
Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua

AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …

milad-fakurian-58z17lnvs4u-unsplash_2

PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research

December 13, 2023
Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM

PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023
Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition

AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023
Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity

Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of …

Latest content